Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Tiede

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 15, 2026
Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI StudyHalet Türkantoz, Christiane Dobbelstein, Richard Greil, et al.
Blood|April 19, 2022
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study resultsFrank W G Leebeek, Flora Peyvandi, Miguel Escobar, et al.
Xenotransplantation|May 9, 2014
Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantationWolf Ramackers, Lars Friedrich, Johannes Klose, et al.
Plos Genetics|April 9, 2020
Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia BSimon Krooss, Sonja Werwitzke, Johannes Kopp, et al.
Plos Genetics|January 28, 2021
Correction: Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia BSimon Krooss, Sonja Werwitzke, Johannes Kopp, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 8, 2018
Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trialSteven R Lentz, Dragana Janic, Kaan Kavakli, et al.
Haematologica|May 9, 2020
International recommendations on the diagnosis and treatment of acquired hemophilia AAndreas Tiede, Peter Collins, Paul Knoebl, et al.
Thrombosis Research|March 28, 2026
Patient characteristics, treatment patterns, and clinical outcomes in patients hospitalized with factor Xa inhibitor-associated major bleeds: A report from the REVERXaL studyRaza Alikhan, May Nour, Andreas Tiede, et al.
Hamostaseologie|December 21, 2022
Erratum: Gentherapie der Hämophilie: Empfehlung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH)Wolfgang Miesbach, Johannes Oldenburg, Robert Klamroth, et al.
Hamostaseologie|December 14, 2022
[Gene therapy of Hemophilia: Recommendations from the German, Austrian, and Swiss Society for Thrombosis and Haemostasis Research (GTH)]Wolfgang Miesbach, Johannes Oldenburg, Robert Klamroth, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 15, 2026
Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI StudyHalet Türkantoz, Christiane Dobbelstein, Richard Greil, et al.
Blood|April 19, 2022
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study resultsFrank W G Leebeek, Flora Peyvandi, Miguel Escobar, et al.
Xenotransplantation|May 9, 2014
Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantationWolf Ramackers, Lars Friedrich, Johannes Klose, et al.
Plos Genetics|April 9, 2020
Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia BSimon Krooss, Sonja Werwitzke, Johannes Kopp, et al.
Plos Genetics|January 28, 2021
Correction: Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia BSimon Krooss, Sonja Werwitzke, Johannes Kopp, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 8, 2018
Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trialSteven R Lentz, Dragana Janic, Kaan Kavakli, et al.
Haematologica|May 9, 2020
International recommendations on the diagnosis and treatment of acquired hemophilia AAndreas Tiede, Peter Collins, Paul Knoebl, et al.
Thrombosis Research|March 28, 2026
Patient characteristics, treatment patterns, and clinical outcomes in patients hospitalized with factor Xa inhibitor-associated major bleeds: A report from the REVERXaL studyRaza Alikhan, May Nour, Andreas Tiede, et al.
Hamostaseologie|December 21, 2022
Erratum: Gentherapie der Hämophilie: Empfehlung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH)Wolfgang Miesbach, Johannes Oldenburg, Robert Klamroth, et al.
Hamostaseologie|December 14, 2022
[Gene therapy of Hemophilia: Recommendations from the German, Austrian, and Swiss Society for Thrombosis and Haemostasis Research (GTH)]Wolfgang Miesbach, Johannes Oldenburg, Robert Klamroth, et al.
Pageof 13